Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

(MedPage Today) — The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced.
The rapid-acting L-type calcium channel blocker is indicated…

Source link : https://www.medpagetoday.com/cardiology/arrhythmias/119016

Author :

Publish date : 2025-12-15 19:08:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

Novel Pills Promising in Relapsed/Refractory Multiple Myeloma

FDA Approves Uplizna for Generalized Myasthenia Gravis

Related Posts

Six Midlife Depressive Symptoms Tied to Dementia

Not Everyone Gets a Mortality Benefit From Reducing Saturated Fats, Study Says

FDA Approves Sexual Desire Drug for Postmenopausal Women

Aspiring Neurosurgeon Died in Brown Campus Shooting

Smartphone-Delivered Digital Therapy Improved Anxiety Symptoms

Lung Cancer Screening Follow-Up Often Inadequate

Six Midlife Depressive Symptoms Tied to Dementia

Not Everyone Gets a Mortality Benefit From Reducing Saturated Fats, Study Says

FDA Approves Sexual Desire Drug for Postmenopausal Women

Aspiring Neurosurgeon Died in Brown Campus Shooting

Smartphone-Delivered Digital Therapy Improved Anxiety Symptoms

Lung Cancer Screening Follow-Up Often Inadequate

Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer

Second Oral Antibiotic for Gonorrhea Gets FDA Green Light

Categories

Archives